Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial

Michael Haude, Hüseyin Ince, Alexandre Abizaid, Ralph Toelg, Pedro Alves Lemos, Clemens von Birgelen, Evald Høj Christiansen, William Wijns, Franz-Josef Neumann, Christoph Kaiser, Eric Eeckhout, Soo Teik Lim, Javier Escaned, Yoshinobu Onuma, Hector M. Garcia-Garcia, Ron Waksman

Research output: Contribution to journalArticleAcademicpeer-review

101 Citations (Scopus)
11 Downloads (Pure)

Abstract

Aims: Metal absorbable scaffolds constitute a conceptually attractive alternative to polymeric scaffolds. Promising 6-month outcomes of a second-generation drug-eluting absorbable metal scaffold (DREAMS 2G), consisting of an absorbable magnesium scaffold backbone, have been reported. We assessed the 12-month safety and performance of this novel device.

Methods and results: The prospective, international, multi-centre, first-in-man BIOSOLVE-II trial enrolled 123 patients with up to two de novo lesions with a reference diameter between 2.2 and 3.7 mm. All patients were scheduled for angiographic follow-up at 6 months, and—if subjects consented—at 12 months. Dual antiplatelet therapy was recommended for 6 months. Quantitative coronary angiography (QCA) parameters remained stable from 6 to 12 months [paired data of 42 patients: in-segment late lumen loss 0.20 ± 0.21 mm vs. 0.25 ± 0.22 mm, P = 0.117, Δ 0.05 ± 0.21 mm (95% CI: −0.01;0.12); in-scaffold late lumen loss 0.37 ± 0.25 mm vs. 0.39 ± 0.27 mm, P = 0.446, Δ 0.03 ± 0.22 (95% CI: −0.04;0.10), respectively]. Intravascular ultrasound and optical coherence tomography findings corroborated the QCA results. Target lesion failure occurred in four patients (3.4%), consisting of one death of unknown cause, one target-vessel myocardial infarction, and two clinically driven target lesion revascularization. No additional event occurred beyond the 6-month follow-up. During the entire follow-up of 12 months, none of the patients experienced a definite or probable scaffold thrombosis.

Conclusion: The novel drug-eluting metal absorbable scaffold DREAMS 2G showed a continuous favourable safety profile up to 12 months and stable angiographic parameters between 6 and 12 months
Original languageEnglish
Pages (from-to)2701-2709
JournalEuropean heart journal
Volume37
Issue number35
DOIs
Publication statusPublished - 2016

Keywords

  • IR-102157
  • METIS-318975
  • Coronary artery disease
  • Bioresorbable
  • Scaffold
  • DREAMS 2G
  • Magnesium
  • PLLA

Fingerprint Dive into the research topics of 'Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial'. Together they form a unique fingerprint.

  • Cite this